CSNK1G3

Summary

CSNK1G3 (casein kinase 1 gamma 3, HGNC:2456) is a protein-coding gene on chromosome 5q23.2, encoding Casein kinase I isoform gamma-3 (Q9Y6M4). Serine/threonine-protein kinase.

This gene encodes a member of a family of serine/threonine protein kinases that phosphorylate caseins and other acidic proteins. A related protein in the African clawed frog participates in the transmission of Wnt/beta-catenin signaling. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.

Source: NCBI Gene 1456 — RefSeq curated summary.

At a glance

• Gene–disease (curated): Tourette syndrome (Limited, GenCC)
• GWAS associations: 26
• Clinical variants (ClinVar): 56 total — 1 pathogenic
• Druggable target: yes — 16 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_001364140

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2456
Approved symbol	CSNK1G3
Name	casein kinase 1 gamma 3
Location	5q23.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000151292
Ensembl biotype	protein_coding
OMIM	604253
Entrez	1456

Gene structure

Transcript identifiers

Ensembl transcripts: 51 — 49 protein_coding, 1 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000345990, ENST00000360683, ENST00000361991, ENST00000508708, ENST00000510842, ENST00000511130, ENST00000512718, ENST00000514131, ENST00000515322, ENST00000521364, ENST00000696905, ENST00000895947, ENST00000895948, ENST00000895949, ENST00000895950, ENST00000895951, ENST00000895952, ENST00000895953, ENST00000895954, ENST00000895955, ENST00000895956, ENST00000895957, ENST00000895958, ENST00000895959, ENST00000895960, ENST00000895961, ENST00000895962, ENST00000895963, ENST00000895964, ENST00000895965, ENST00000895966, ENST00000895967, ENST00000895968, ENST00000895969, ENST00000895970, ENST00000895971, ENST00000895972, ENST00000895973, ENST00000895974, ENST00000895975, ENST00000926407, ENST00000926408, ENST00000926409, ENST00000962235, ENST00000962236, ENST00000962237, ENST00000962238, ENST00000962239, ENST00000962240, ENST00000962241, ENST00000962242

RefSeq mRNA: 16 — MANE Select: NM_001364140 NM_001031812, NM_001044723, NM_001270572, NM_001270573, NM_001270574, NM_001364140, NM_001364141, NM_001364143, NM_001364144, NM_001364145, NM_001364146, NM_001364147, NM_001364148, NM_001364149, NM_001364150, NM_004384

CCDS: CCDS34218, CCDS4135, CCDS43355, CCDS59491, CCDS59492, CCDS59493, CCDS93772

Canonical transcript exons

ENST00000696905 — 14 exons

Exon	Start	End
ENSE00000998768	123604724	123604830
ENSE00000998775	123588427	123588511
ENSE00000998778	123575729	123575963
ENSE00001082724	123590410	123590558
ENSE00001120965	123591319	123591414
ENSE00001331321	123605339	123605362
ENSE00001521677	123545417	123545841
ENSE00001521680	123512177	123512570
ENSE00001736478	123588068	123588153
ENSE00003597406	123573393	123573541
ENSE00003663267	123557495	123557564
ENSE00003692293	123553107	123553147
ENSE00003967641	123595039	123595134
ENSE00003968849	123614342	123617049

Expression profiles

Bgee: expression breadth ubiquitous, 280 present calls, max score 95.71.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 33.2405 / max 234.2416, expressed in 1816 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
58234	20.9142	1797
58233	6.2264	1670
58232	1.7460	1042
58231	1.6483	944
58237	1.2289	689
58235	0.7236	470
58238	0.5138	248
58236	0.2393	72

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	95.71	gold quality
buccal mucosa cell	CL:0002336	94.32	gold quality
endothelial cell	CL:0000115	93.90	silver quality
cartilage tissue	UBERON:0002418	93.73	gold quality
trigeminal ganglion	UBERON:0001675	93.49	gold quality
jejunal mucosa	UBERON:0000399	92.91	gold quality
colonic epithelium	UBERON:0000397	92.83	gold quality
pericardium	UBERON:0002407	92.72	gold quality
dorsal root ganglion	UBERON:0000044	92.47	gold quality
Brodmann (1909) area 23	UBERON:0013554	92.32	gold quality
germinal epithelium of ovary	UBERON:0001304	92.15	gold quality
adrenal tissue	UBERON:0018303	92.07	gold quality
cortical plate	UBERON:0005343	91.15	gold quality
tendon	UBERON:0000043	91.03	gold quality
rectum	UBERON:0001052	90.95	gold quality
mucosa of sigmoid colon	UBERON:0004993	90.93	gold quality
synovial joint	UBERON:0002217	90.92	gold quality
corpus callosum	UBERON:0002336	90.59	gold quality
colonic mucosa	UBERON:0000317	90.46	gold quality
islet of Langerhans	UBERON:0000006	90.33	gold quality
jejunum	UBERON:0002115	90.16	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	90.01	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	89.95	gold quality
pons	UBERON:0000988	89.86	gold quality
ventricular zone	UBERON:0003053	89.85	gold quality
ganglionic eminence	UBERON:0004023	89.74	gold quality
secondary oocyte	CL:0000655	89.49	gold quality
superficial temporal artery	UBERON:0001614	89.47	gold quality
oocyte	CL:0000023	89.45	gold quality
oviduct epithelium	UBERON:0004804	89.24	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.92

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

218 targeting CSNK1G3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-23A-3P	99.95	74.24	3163

Literature-anchored findings (GeneRIF, showing 4)

• Intratumoral heterogeneity of CSNK1G3 mutations, a casein kinase 1, in colon cancers. (PMID:32241596)
• Protein proximity networks and functional evaluation of the casein kinase 1 gamma family reveal unique roles for CK1gamma3 in WNT signaling. (PMID:35487243)
• circCsnk1g3- and circAnkib1-regulated interferon responses in sarcoma promote tumorigenesis by shaping the immune microenvironment. (PMID:36433954)
• A novel nanoplatform-based circCSNK1G3 affects CBX7 protein and promotes glioma cell growth. (PMID:39033888)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
mus_musculus	Csnk1g3	ENSMUSG00000073563
rattus_norvegicus	Csnk1g3	ENSRNOG00000016677
drosophila_melanogaster	CG9962	FBGN0031441
caenorhabditis_elegans	csnk-1	WBGENE00013709

Paralogs (12): VRK2 (ENSG00000028116), CDC7 (ENSG00000097046), VRK1 (ENSG00000100749), VRK3 (ENSG00000105053), CSNK1A1 (ENSG00000113712), TTBK2 (ENSG00000128881), CSNK1G2 (ENSG00000133275), CSNK1D (ENSG00000141551), TTBK1 (ENSG00000146216), CSNK1G1 (ENSG00000169118), CSNK1A1L (ENSG00000180138), CSNK1E (ENSG00000213923)

Protein

Protein identifiers

Casein kinase I isoform gamma-3 — Q9Y6M4 (reviewed: Q9Y6M4)

All UniProt accessions (3): Q9Y6M4, A0A8V8TKT3, H0YBN6

UniProt curated annotations — full annotation on UniProt →

Function. Serine/threonine-protein kinase. Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates. It can phosphorylate a large number of proteins. Participates in Wnt signaling. Regulates fast synaptic transmission mediated by glutamate.

Subunit / interactions. Monomer.

Subcellular location. Cytoplasm.

Post-translational modifications. Autophosphorylated.

Activity regulation. Inhibited by triazolodiamine 1 (5-amino-3-([4-(aminosulfonyl)phenyl]amino)-N-(2,6-difluorophenyl)-1H-1,2,4-triazole-1-carbothioamide), (S)-propane-1,2-diol, 2-({6-[(3-chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)-3-methylbutan-1-ol, N2-[(1R,2S)-2-aminocyclohexyl]-N6-(3-chlorophenyl)-9-ethyl-9H-purine-2,6-diamine and 4-amino-2-(3-chloroanilino)-1,3-thiazol-5-ylmethanone.

Similarity. Belongs to the protein kinase superfamily. CK1 Ser/Thr protein kinase family. Casein kinase I subfamily.

Isoforms (6)

UniProt ID	Names	Canonical?
Q9Y6M4-1	1, 3	yes
Q9Y6M4-2	2, 3L, CSNK1G3L
Q9Y6M4-3	3
Q9Y6M4-4	4
Q9Y6M4-5	5
Q9Y6M4-6	6

RefSeq proteins (16): NP_001026982, NP_001038188, NP_001257501, NP_001257502, NP_001257503, NP_001351069, NP_001351070, NP_001351072, NP_001351073, NP_001351074, NP_001351075, NP_001351076, NP_001351077, NP_001351078, NP_001351079, NP_004375 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR008271	Ser/Thr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR017441	Protein_kinase_ATP_BS	Binding_site
IPR022247	Casein_kinase-1_gamma_C	Domain
IPR050235	CK1_Ser-Thr_kinase-like	Family

Pfam: PF00069, PF12605

Enzyme classification (BRENDA):

• EC 2.7.11.1 — non-specific serine/threonine protein kinase (BRENDA: 71 organisms, 682 substrates, 228 inhibitors, 23 Km, 6 kcat entries)

Substrate kinetics (BRENDA)

8 substrates with measured Km, best-characterized 8. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ATP	0.0007–0.64	11
KKRAARATSNVFA	0.013–0.045	3
PAH1 PHOSPHATIDATE PHOSPHATASE	0.0002	2
RRRLSSLRA	0.0036–0.0037	2
GTP	0.46	1
KKRAARASSNVFA	0.02	1
LYS-LYS-PHE-ASN-ARG-THR-LEU-SER-VAL-ALA	0.0093	1
MYELIN BASIC PROTEIN	0.145	1

Catalyzed reactions (Rhea), 2 shown:

• L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+) (RHEA:17989)
• L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+) (RHEA:46608)

UniProt features (57 total): helix 11, strand 10, turn 9, modified residue 6, splice variant 5, sequence conflict 4, compositionally biased region 4, region of interest 3, binding site 2, chain 1, domain 1, active site 1

Structure

Experimental structures (PDB)

10 structures.

PDB	Method	Resolution (Å)
2IZR	X-RAY DIFFRACTION	1.3
6GRO	X-RAY DIFFRACTION	1.45
2IZU	X-RAY DIFFRACTION	1.85
2CHL	X-RAY DIFFRACTION	1.95
2IZS	X-RAY DIFFRACTION	1.95
2IZT	X-RAY DIFFRACTION	2
4G17	X-RAY DIFFRACTION	2.1
4G16	X-RAY DIFFRACTION	2.3
4HGL	X-RAY DIFFRACTION	2.4
4HGS	X-RAY DIFFRACTION	2.4

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y6M4-F1	77.08	0.65

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 162 (proton acceptor)

Ligand- & substrate-binding residues (2): 49–57; 72

Post-translational modifications (6): 1, 413, 366, 367, 291, 254

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 219 (showing top): RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, GGTGTGT_MIR329, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, KEGG_HEDGEHOG_SIGNALING_PATHWAY, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_REGULATION_OF_WNT_SIGNALING_PATHWAY, FOXO4_01, FOXO1_01, FOXD3_01, AAACCAC_MIR140, MILI_PSEUDOPODIA_HAPTOTAXIS_UP, GOBP_CANONICAL_WNT_SIGNALING_PATHWAY, PID_FOXO_PATHWAY, ZHAN_MULTIPLE_MYELOMA_HP_UP

GO Biological Process (6): endocytosis (GO:0006897), signal transduction (GO:0007165), Wnt signaling pathway (GO:0016055), protein modification process (GO:0036211), positive regulation of canonical Wnt signaling pathway (GO:0090263), protein phosphorylation (GO:0006468)

GO Molecular Function (8): protein kinase activity (GO:0004672), protein serine/threonine kinase activity (GO:0004674), ATP binding (GO:0005524), protein serine kinase activity (GO:0106310), nucleotide binding (GO:0000166), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740)

GO Cellular Component (3): nucleus (GO:0005634), cytoplasm (GO:0005737), plasma membrane (GO:0005886)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein kinase activity	2
vesicle budding from membrane	1
membrane invagination	1
vesicle-mediated transport	1
import into cell	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
cell surface receptor signaling pathway	1
protein metabolic process	1
macromolecule modification	1
positive regulation of Wnt signaling pathway	1
canonical Wnt signaling pathway	1
regulation of canonical Wnt signaling pathway	1
phosphorylation	1
protein modification process	1
kinase activity	1
phosphotransferase activity, alcohol group as acceptor	1
catalytic activity, acting on a protein	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
transferase activity, transferring phosphorus-containing groups	1
catalytic activity	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cellular anatomical structure	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

1288 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CSNK1G3	CTNNA2	P26232	462
CSNK1G3	LRP8	Q14114	430
CSNK1G3	LRP1B	Q9NZR2	410
CSNK1G3	EDAR	Q9UNE0	398
CSNK1G3	WNT2	P09544	391
CSNK1G3	CSNK1G1	Q9HCP0	390
CSNK1G3	PDIK1L	Q8N165	384
CSNK1G3	NEO1	Q92859	381
CSNK1G3	UBAC2	Q8NBM4	381
CSNK1G3	LRP6	O75581	376
CSNK1G3	TMEM220	Q6QAJ8	369
CSNK1G3	ZNF433	Q8N7K0	358
CSNK1G3	ALB	P02768	351
CSNK1G3	SLC35A2	P78381	336
CSNK1G3	N0E472	N0E472	327

IntAct

79 interactions, top by confidence:

A	B	Type	Score
MED21	MED19	psi-mi:“MI:0914”(association)	0.880
GPR156	PLD2	psi-mi:“MI:0914”(association)	0.640
CSNK1G3	CSNK1G2	psi-mi:“MI:0914”(association)	0.640
CSNK1G1	CSNK1G3	psi-mi:“MI:0915”(physical association)	0.620
SLC31A1	C2orf72	psi-mi:“MI:0914”(association)	0.530
GJB7	PALM3	psi-mi:“MI:0914”(association)	0.530
S1PR2	PALM3	psi-mi:“MI:0914”(association)	0.530
TPCN2	AP3B1	psi-mi:“MI:0914”(association)	0.530
MRAP2	GOLIM4	psi-mi:“MI:0914”(association)	0.530
CSNK1G2	GINS1	psi-mi:“MI:0914”(association)	0.530
CSNK1G2	MAPK14	psi-mi:“MI:0914”(association)	0.530
PNMA2	CCDC85C	psi-mi:“MI:0914”(association)	0.530
NRAS	ESYT2	psi-mi:“MI:2364”(proximity)	0.480
CSNK1G3	LRRK2	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
GPC1	SNAP23	psi-mi:“MI:0915”(physical association)	0.400
GPC1	GANAB	psi-mi:“MI:0915”(physical association)	0.400
M2	IPO5	psi-mi:“MI:0914”(association)	0.350
	SGK1	psi-mi:“MI:0914”(association)	0.350
	TBKBP1	psi-mi:“MI:0914”(association)	0.350
	AHRR	psi-mi:“MI:0914”(association)	0.350
	PAK4	psi-mi:“MI:0914”(association)	0.350
ZDHHC5	IGKV2D-24	psi-mi:“MI:0914”(association)	0.350
CSNK1G2	ZSWIM8	psi-mi:“MI:0914”(association)	0.350
HASPIN	MYO1C	psi-mi:“MI:0914”(association)	0.350
CSNK1G3	ACACB	psi-mi:“MI:0914”(association)	0.350
CSNK1G3	YWHAG	psi-mi:“MI:0914”(association)	0.350
SAA1	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
PROSER2	VWA8	psi-mi:“MI:0914”(association)	0.350
TSPAN10	KLRG2	psi-mi:“MI:0914”(association)	0.350
PTP4A3	POTEF	psi-mi:“MI:0914”(association)	0.350

BioGRID (182): CSNK1G3 (Biochemical Activity), CSNK1G3 (Affinity Capture-MS), CSNK1G3 (Affinity Capture-MS), CSNK1G3 (Affinity Capture-MS), CSNK1G3 (Affinity Capture-MS), CSNK1G3 (Affinity Capture-MS), CSNK1G3 (Affinity Capture-MS), CSNK1G3 (Affinity Capture-MS), CSNK1G3 (Affinity Capture-Western), UBXN7 (Affinity Capture-Western), CSNK1G3 (Affinity Capture-MS), CSNK1G1 (Affinity Capture-MS), ANKRD13D (Affinity Capture-MS), CSNK1G3 (Affinity Capture-MS), CSNK1G3 (Affinity Capture-MS)

ESM2 similar proteins: A7E3X2, O74135, P29295, P35508, P40233, P40234, P40236, P42158, P48730, P49674, P51566, P78368, Q03141, Q06486, Q20471, Q39050, Q4R9A9, Q556Y4, Q5BP74, Q5PRD4, Q5R4V3, Q5RC72, Q5XF24, Q5ZJS0, Q5ZLL1, Q62761, Q62762, Q62763, Q6K9N1, Q6NRT0, Q6P3K7, Q6P647, Q7T2E3, Q8BTH8, Q8BVP5, Q8C4X2, Q8LPI7, Q8LPJ1, Q8VYK9, Q8WQ99

Diamond homologs: A7E3X2, B9VVJ6, O15726, O19175, O74135, O76324, O80888, P16912, P22517, P23291, P23292, P28327, P29295, P34516, P34633, P35507, P35508, P35509, P39962, P40230, P40233, P40234, P40235, P40236, P42158, P42168, P48729, P48730, P49615, P49674, P51166, P54367, P67827, P67828, P67829, P67962, P67963, P78368, P81123, P97633

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
CSNK1G3	“up-regulates quantity by stabilization”	LYN	phosphorylation
CSNK1G3	“up-regulates activity”	LRP6	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 120 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Signaling by SCF-KIT	5	16.6×	8e-04
Respiratory Syncytial Virus Infection Pathway	5	13.1×	2e-03
RSV-host interactions	6	12.5×	7e-04
Signaling by BRAF and RAF1 fusions	5	11.4×	2e-03
Cytokine Signaling in Immune system	8	4.3×	6e-03
Infectious disease	11	3.6×	3e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

56 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	35
Likely benign	3
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
150374	GRCh38/hg38 5q22.1-23.3(chr5:110687442-130103838)x1	Pathogenic

SpliceAI

1475 predictions. Top by Δscore:

Variant	Effect	Δscore
5:123545842:G:GA	donor_loss	1.0000
5:123545842:G:GG	donor_gain	1.0000
5:123545843:T:A	donor_loss	1.0000
5:123554808:G:GT	donor_gain	1.0000
5:123557489:A:AG	acceptor_gain	1.0000
5:123557490:A:G	acceptor_gain	1.0000
5:123573388:CCCA:C	acceptor_loss	1.0000
5:123573390:CA:C	acceptor_loss	1.0000
5:123573391:A:AG	acceptor_gain	1.0000
5:123573391:AGAT:A	acceptor_gain	1.0000
5:123573391:AGATG:A	acceptor_gain	1.0000
5:123573392:G:A	acceptor_loss	1.0000
5:123573392:G:GT	acceptor_gain	1.0000
5:123573392:GA:G	acceptor_gain	1.0000
5:123573392:GAT:G	acceptor_gain	1.0000
5:123573392:GATG:G	acceptor_gain	1.0000
5:123573392:GATGG:G	acceptor_gain	1.0000
5:123573538:ACTG:A	donor_gain	1.0000
5:123573541:GGTA:G	donor_loss	1.0000
5:123573542:G:A	donor_loss	1.0000
5:123573542:G:GG	donor_gain	1.0000
5:123575721:A:AG	acceptor_gain	1.0000
5:123588066:A:AG	acceptor_gain	1.0000
5:123588067:G:GA	acceptor_gain	1.0000
5:123588421:TTTTA:T	acceptor_loss	1.0000
5:123588422:TTTA:T	acceptor_loss	1.0000
5:123588423:TTA:T	acceptor_loss	1.0000
5:123588424:TA:T	acceptor_loss	1.0000
5:123588425:A:AG	acceptor_gain	1.0000
5:123588426:G:GG	acceptor_gain	1.0000

AlphaMissense

3000 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:123545779:T:A	V39D	1.000
5:123545781:G:A	G40R	1.000
5:123545781:G:C	G40R	1.000
5:123545782:G:A	G40E	1.000
5:123545782:G:T	G40V	1.000
5:123545790:T:C	F43L	1.000
5:123545791:T:C	F43S	1.000
5:123545791:T:G	F43C	1.000
5:123545792:T:A	F43L	1.000
5:123545792:T:G	F43L	1.000
5:123545797:T:A	V45D	1.000
5:123545809:T:A	I49N	1.000
5:123545811:G:A	G50R	1.000
5:123545811:G:C	G50R	1.000
5:123545812:G:A	G50E	1.000
5:123545812:G:T	G50V	1.000
5:123545817:G:A	G52S	1.000
5:123545817:G:C	G52R	1.000
5:123545817:G:T	G52C	1.000
5:123545818:G:A	G52D	1.000
5:123545818:G:C	G52A	1.000
5:123545818:G:T	G52V	1.000
5:123545822:T:A	N53K	1.000
5:123545822:T:G	N53K	1.000
5:123545823:T:A	F54I	1.000
5:123545823:T:C	F54L	1.000
5:123545823:T:G	F54V	1.000
5:123545824:T:C	F54S	1.000
5:123545824:T:G	F54C	1.000
5:123545825:T:A	F54L	1.000

dbSNP variants (sampled 300 via entrez): RS1000012535 (5:123516351 T>C), RS1000044655 (5:123552386 C>T), RS1000065318 (5:123612299 A>G), RS1000070508 (5:123545499 C>T), RS1000080910 (5:123538876 T>A,G), RS1000120943 (5:123571510 A>C,G,T), RS1000145525 (5:123530133 A>G), RS1000173273 (5:123534872 G>A), RS1000229382 (5:123527022 A>G), RS1000246965 (5:123579135 C>T), RS1000269927 (5:123608693 A>G), RS1000311731 (5:123568396 C>G,T), RS1000314618 (5:123608969 G>A,T), RS1000322808 (5:123586362 A>G), RS1000323256 (5:123546027 G>A)

Disease associations

OMIM: gene MIM:604253 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
Tourette syndrome	Limited	Unknown

Mondo (1): Tourette syndrome (MONDO:0007661)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

26 associations (top):

Study	Trait	p-value
GCST000406_12	Amyotrophic lateral sclerosis	3.000000e-06
GCST002221_16	Cholesterol, total	2.000000e-09
GCST002222_57	LDL cholesterol	4.000000e-12
GCST002928_27	Nickel levels	8.000000e-06
GCST003833_6	Adult asthma	1.000000e-06
GCST004233_13	LDL cholesterol levels	3.000000e-12
GCST004235_45	Total cholesterol levels	2.000000e-09
GCST005331_2	CSF tryptophan concentration in tuberculous meningitis	4.000000e-06
GCST005348_171	Total body bone mineral density	8.000000e-12
GCST005348_73	Total body bone mineral density	1.000000e-09
GCST005559_11	Virologic severity in Herpes simplex virus type 2 infection	4.000000e-07
GCST006230_1	Pulse pressure	9.000000e-07
GCST006258_8	Diastolic blood pressure	2.000000e-11
GCST006259_38	Systolic blood pressure	1.000000e-06
GCST006288_216	Heel bone mineral density	3.000000e-10
GCST006288_536	Heel bone mineral density	2.000000e-10
GCST006612_23	LDL cholesterol	2.000000e-08
GCST006979_117	Heel bone mineral density	3.000000e-30
GCST007268_19	Diastolic blood pressure	1.000000e-11
GCST007576_195	Chronotype	2.000000e-09
GCST009391_595	Metabolite levels	1.000000e-08
GCST010204_89	Low density lipoprotein cholesterol levels	2.000000e-19
GCST010243_165	Apolipoprotein B levels	2.000000e-21
GCST010245_147	LDL cholesterol levels	4.000000e-19
GCST011772_2	Rapid response to perioperative phenylephrine (change in systolic blood pressure)	5.000000e-08
GCST90002404_212	Red cell distribution width	8.000000e-12

EFO canonical traits (13, from GWAS)

EFO ID	Trait name
EFO:0004574	total cholesterol measurement
EFO:0004611	low density lipoprotein cholesterol measurement
EFO:0008534	tryptophan measurement
EFO:0009010	HSV2 virologic severity measurement
EFO:0005763	pulse pressure measurement
EFO:0006336	diastolic blood pressure
EFO:0006335	systolic blood pressure
EFO:0009270	heel bone mineral density
EFO:0008328	chronotype measurement
EFO:0010502	indoxyl sulfate measurement
EFO:0004615	apolipoprotein B measurement
EFO:0006944	systolic blood pressure change measurement
EFO:0009188	Red cell distribution width

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D005879	Tourette Syndrome	C10.228.140.079.898; C10.228.662.825.800; C10.574.500.850; C16.320.400.820; F03.625.992.850

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5084 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

16 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 101,368 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL180022	NERATINIB	4	9,404
CHEMBL535	SUNITINIB	4	79,020
CHEMBL14762	SELICICLIB	2	3,787
CHEMBL1614713	CC-401	2	389
CHEMBL1721885	SU-014813	2	363
CHEMBL1967878	CENISERTIB	2	358
CHEMBL230011	TG100-115	2	1,504
CHEMBL363648	TAK-715	2	442
CHEMBL513909	BI-2536	2	895
CHEMBL1908397	KW-2449	1	622
CHEMBL260933	GS 6201	1	298
CHEMBL3544966	GSK-1059615	1	1,928
CHEMBL3545083	RGB-286638	1	551
CHEMBL482967	CYC-116	1	651
CHEMBL571948	Y-39983	1	705
CHEMBL574738	AST-487	1	451

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — Casein kinase 1 (CK1) family

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
SGC-CK1γ-1	Inhibition	6.02	pIC50

Binding affinities (BindingDB)

5 measured of 5 human assays (5 total across all organisms); most potent 5 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
(2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol	KD	260 nM
1-[4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[[6-(methylamino)-4-pyrimidinyl]oxy]phenyl]urea	KD	1400 nM
5-[(Z)-(5-fluoranyl-2-oxidanylidene-1H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[(2S)-3-morpholin-4-yl-2-oxidanyl-propyl]-1H-pyrrole-3-carboxamide	KD	2600 nM
1-Acyl-1H-[1,2,4]triazole-3,5-diamine Analogue 3b	KD	3100 nM
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	KD	3500 nM

ChEMBL bioactivities

201 potent at pChembl≥5 of 202 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.10	Ki	7.943	nM	CHEMBL1999931
8.00	Ki	10	nM	CHEMBL1965660
7.70	Ki	19.95	nM	CHEMBL1969588
7.70	Ki	19.95	nM	CHEMBL2003638
7.50	Ki	31.62	nM	CHEMBL1981079
7.50	Ki	31.62	nM	CHEMBL2006439
7.50	Ki	31.62	nM	CHEMBL1990288
7.43	Kd	37	nM	CHEMBL5434183
7.40	Ki	39.81	nM	CHEMBL1996066
7.30	Ki	50.12	nM	CHEMBL1966628
7.10	Ki	79.43	nM	CHEMBL1964290
7.10	Ki	79.43	nM	CHEMBL1998159
7.10	Ki	79.43	nM	CHEMBL1991078
7.01	Kd	97	nM	CC-401
7.01	Kd	97	nM	AST-487
7.00	Kd	100	nM	CHEMBL1349996
7.00	Ki	100	nM	CHEMBL1989646
7.00	Ki	100	nM	CHEMBL1970903
7.00	Ki	100	nM	CHEMBL1994830
6.90	Ki	125.9	nM	CHEMBL1975900
6.90	Ki	125.9	nM	CHEMBL1982361
6.82	Kd	150	nM	CHEMBL5414359
6.80	Ki	158.5	nM	CHEMBL1980489
6.80	Ki	158.5	nM	CHEMBL225519
6.80	Ki	158.5	nM	CHEMBL1978448
6.80	Ki	158.5	nM	CHEMBL1969843
6.80	Ki	158.5	nM	CHEMBL396523
6.80	Ki	158.5	nM	CHEMBL1991063
6.70	Ki	199.5	nM	CHEMBL1990288
6.62	Kd	240	nM	SUNITINIB
6.60	Ki	251.2	nM	CHEMBL1995813
6.60	Ki	251.2	nM	CHEMBL1971186
6.60	Ki	251.2	nM	CHEMBL1994864
6.60	Ki	251.2	nM	CHEMBL1974870
6.60	Ki	251.2	nM	CHEMBL243088
6.54	Kd	290	nM	CHEMBL5416758
6.54	Kd	290	nM	CHEMBL408982
6.50	Ki	316.2	nM	CHEMBL1988173
6.50	Ki	316.2	nM	CHEMBL1986781
6.40	Ki	398.1	nM	CHEMBL244378
6.37	Kd	427	nM	CHEMBL3688339
6.34	IC50	460	nM	CHEMBL4101902
6.30	Ki	501.2	nM	CHEMBL2005936
6.30	Ki	501.2	nM	CHEMBL1972158
6.30	Ki	501.2	nM	CHEMBL1965836
6.30	Ki	501.2	nM	CHEMBL1986186
6.30	Ki	501.2	nM	CHEMBL1979252
6.30	Ki	501.2	nM	CHEMBL1988153
6.30	Ki	501.2	nM	CHEMBL1990885
6.30	Ki	501.2	nM	CHEMBL1998414

PubChem BioAssay actives

37 with measured affinity, of 1586 total; 29 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
5-[(5S)-5-(4-chlorophenyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl]-3-methyl-2H-indazole	2030650: Binding affinity to CSNK1G3 (unknown origin) assessed as dissociation constant by competitive binding assay	kd	0.0370	uM
3-[3-(2-piperidin-1-ylethoxy)phenyl]-5-(1H-1,2,4-triazol-5-yl)-1H-indazole	1424966: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0970	uM
1-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[6-(methylamino)pyrimidin-4-yl]oxyphenyl]urea	435905: Binding constant for full-length CSNK1G3	kd	0.0970	uM
(1E)-1-(3-ethyl-5-methoxy-1,3-benzothiazol-2-ylidene)propan-2-one	1722615: Binding affinity to CSNK1G3 (unknown origin)	kd	0.1000	uM
5-[4-[(4-chlorophenyl)methyl]-5-methyl-1,2,4-triazol-3-yl]-3-methyl-2H-indazole	2030650: Binding affinity to CSNK1G3 (unknown origin) assessed as dissociation constant by competitive binding assay	kd	0.1500	uM
Sunitinib	435905: Binding constant for full-length CSNK1G3	kd	0.2400	uM
5-[(5S)-5-(4-chlorophenyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl]-3-methyl-2H-pyrazolo[4,3-b]pyridine	2030650: Binding affinity to CSNK1G3 (unknown origin) assessed as dissociation constant by competitive binding assay	kd	0.2900	uM
(1Z)-1-(3-ethyl-5-methoxy-1,3-benzothiazol-2-ylidene)propan-2-one	445574: Binding affinity to CSNK1G3 assessed as dissociation constant	kd	0.2900	uM
1-[6-(3,5-dichloro-4-hydroxyphenyl)-4-[[4-[(dimethylamino)methyl]cyclohexyl]amino]-1,5-naphthyridin-3-yl]ethanone	1424966: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.4270	uM
4-[3-amino-6-[1-methyl-5-(1-phenylcyclopropyl)-1,2,4-triazol-3-yl]pyrazin-2-yl]-2-fluorobenzamide	1434404: Inhibition of full length GST-tagged recombinant human CSNK1G3 expressed in baculovirus expression system	ic50	0.4600	uM
5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	435905: Binding constant for full-length CSNK1G3	kd	0.5700	uM
5-[(5S)-5-(4-chlorophenyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl]-3-methyl-2H-pyrazolo[3,4-b]pyridine	2030650: Binding affinity to CSNK1G3 (unknown origin) assessed as dissociation constant by competitive binding assay	kd	0.6700	uM
4-[(1R)-1-aminoethyl]-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)benzamide	1424966: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.7820	uM
N-(2,2-difluoro-5H-[1,3]dioxolo[4,5-f]benzimidazol-6-yl)-3-methoxybenzamide	1162642: Inhibition of GST-tagged human CK1gamma3 expressed in Escherichia coli using using alpha casein substrate by SDS-PAGE based autoradiography	ic50	0.8000	uM
N-(2,2-difluoro-5H-[1,3]dioxolo[4,5-f]benzimidazol-6-yl)-2-[[2-(trifluoromethoxy)benzoyl]amino]-1,3-thiazole-4-carboxamide	1162642: Inhibition of GST-tagged human CK1gamma3 expressed in Escherichia coli using using alpha casein substrate by SDS-PAGE based autoradiography	ic50	0.8100	uM
3-methyl-5-[5-methyl-4-[[4-(trifluoromethyl)phenyl]methyl]-1,2,4-triazol-3-yl]-2H-indazole	2030650: Binding affinity to CSNK1G3 (unknown origin) assessed as dissociation constant by competitive binding assay	kd	0.8600	uM
(2S)-1-[[5-(3-methyl-2H-indazol-5-yl)-3-pyridinyl]oxy]-3-phenylpropan-2-amine	624949: Binding constant for CSNK1G3 kinase domain	kd	0.9100	uM
[4-[(E)-2-(1H-indazol-3-yl)ethenyl]phenyl]-piperazin-1-ylmethanone	624949: Binding constant for CSNK1G3 kinase domain	kd	1.2000	uM
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	1715393: Inhibition of human CK1gamma3 using KRRRAL[pS]VASLPGL as substrate by [gamma-33P]-ATP assay	ic50	1.9800	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148162: Binding affinity to human CSNK1G3 incubated for 45 mins by Kinobead based pull down assay	kd	2.1730	uM
4-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide	624949: Binding constant for CSNK1G3 kinase domain	kd	2.4000	uM
2-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-5-ol	624949: Binding constant for CSNK1G3 kinase domain	kd	2.6000	uM
(5Z)-5-[(4-pyridin-4-ylquinolin-6-yl)methylidene]-1,3-thiazolidine-2,4-dione	1424966: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	2.8610	uM
(2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol	435905: Binding constant for full-length CSNK1G3	kd	2.9000	uM
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148162: Binding affinity to human CSNK1G3 incubated for 45 mins by Kinobead based pull down assay	kd	6.1372	uM
4-methyl-5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine	1424966: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	7.5360	uM
Neratinib	624949: Binding constant for CSNK1G3 kinase domain	kd	7.8000	uM
4-[[5-amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide	435905: Binding constant for full-length CSNK1G3	kd	7.9000	uM
3-[2,4-diamino-7-(3-hydroxyphenyl)pteridin-6-yl]phenol	624949: Binding constant for CSNK1G3 kinase domain	kd	8.7000	uM

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	2
aristolochic acid I	decreases expression	1
GSK-J4	increases expression	1
FR900359	increases phosphorylation	1
ginger extract	affects cotreatment, affects expression, increases abundance	1
dicrotophos	decreases expression	1
alpha-pinene	affects cotreatment, increases expression, increases abundance	1
bisphenol A	affects cotreatment, affects expression, increases abundance	1
arsenite	affects binding, decreases reaction	1
mono-(2-ethylhexyl)phthalate	increases abundance, increases methylation	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
sodium arsenite	affects cotreatment, increases abundance, increases expression	1
2-bromopalmitate	decreases reaction, increases abundance, increases palmitoylation	1
manganese chloride	increases abundance, increases expression, affects cotreatment	1
methacrylaldehyde	affects cotreatment, increases expression, increases abundance	1
beta-methylcholine	affects expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	increases reaction, affects binding	1
jinfukang	decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Leflunomide	increases expression	1
Acrolein	increases abundance, affects cotreatment, increases expression	1
Air Pollutants	increases abundance, increases expression, affects cotreatment	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Cadmium	decreases reaction, increases abundance, increases palmitoylation	1
Caffeine	decreases phosphorylation	1
Coumestrol	decreases expression	1
Diethylhexyl Phthalate	increases abundance, increases methylation	1
Doxorubicin	decreases expression	1
Manganese	increases abundance, increases expression, affects cotreatment	1

ChEMBL screening assays

216 unique, capped per target: 215 binding, 1 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1034090	Binding	Inhibition of CSNK1G3 at 3 uM	Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors. — J Med Chem
CHEMBL1964116	Functional	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK1G3	PubChem BioAssay data set

Cellosaurus cell lines

6 cell lines: 5 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D7N0	Ubigene A-549 CSNK1G3 KO	Cancer cell line	Male
CVCL_D8JH	Ubigene HCT 116 CSNK1G3 KO	Cancer cell line	Male
CVCL_D9CI	Ubigene HEK293 CSNK1G3 KO	Transformed cell line	Female
CVCL_E0B7	Ubigene HeLa CSNK1G3 KO	Cancer cell line	Female
CVCL_SJ89	HAP1 CSNK1G3 (-) 1	Cancer cell line	Male
CVCL_SJ90	HAP1 CSNK1G3 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

183 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00152750	PHASE4	UNKNOWN	Study of Clonidine on Sleep Architecture in Children With Tourette’s Syndrome (TS) and Comorbid ADHD
NCT00226824	PHASE4	TERMINATED	Safety Study of Galantamine in Tic Disorders
NCT00241176	PHASE4	COMPLETED	Open Label Trial of Aripiprazole in Children and Adolescents With Tourette’s Disorder
NCT00370838	PHASE4	COMPLETED	Comparison of Keppra and Clonidine in the Treatment of Tics
NCT01018056	PHASE4	COMPLETED	Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
NCT01547000	PHASE4	COMPLETED	Guanfacine in Children With Tic Disorders
NCT03239210	PHASE4	COMPLETED	Effects of Ondansetron in Obsessive-compulsive and Tic Disorders
NCT00004376	PHASE3	COMPLETED	Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder
NCT00206323	PHASE3	COMPLETED	A Randomized, Placebo-controlled, Tourette Syndrome Study.
NCT00206336	PHASE3	COMPLETED	An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.
NCT00478842	PHASE3	COMPLETED	Pallidal Stimulation and Gilles de la Tourette Syndrome
NCT00681863	PHASE3	TERMINATED	Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome
NCT01501695	PHASE3	COMPLETED	Phase III Study of 5LGr to Treat Tic Disorder
NCT03087201	PHASE3	COMPLETED	CANNAbinoids in the Treatment of TICS (CANNA-TICS)
NCT03487783	PHASE3	COMPLETED	Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette’s Syndrome
NCT03567291	PHASE3	TERMINATED	Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents
NCT03571256	PHASE3	COMPLETED	A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)
NCT06021522	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette’s Disorder
NCT00004393	PHASE2	COMPLETED	Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome
NCT00004652	PHASE2	COMPLETED	Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome
NCT00231985	PHASE2	COMPLETED	Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic Disorder
NCT00311909	PHASE2	COMPLETED	Thalamic Deep Brain Stimulation for Tourette Syndrome
NCT00529308	PHASE2	COMPLETED	Transcranial Magnetic Stimulation (TMS) for Individuals With Tourette’s Syndrome
NCT00558467	PHASE2	COMPLETED	Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria
NCT01043549	PHASE2	TERMINATED	Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome
NCT01133353	PHASE2	WITHDRAWN	A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjects With Tourette’s Syndrome
NCT01475383	PHASE2	WITHDRAWN	Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette’s Syndrome
NCT01647269	PHASE2	COMPLETED	A Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Tourette Syndrome
NCT01904773	PHASE2	COMPLETED	Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette’s Disorder
NCT02102698	PHASE2	COMPLETED	Ecopipam Treatment of Tourette’s Syndrome in Subjects 7-17 Years
NCT02217007	PHASE2	WITHDRAWN	A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome
NCT02247206	PHASE2	COMPLETED	VoIP Delivered Behavior Therapy for Tourette Syndrome
NCT02581865	PHASE2	COMPLETED	Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome
NCT02619084	PHASE2	COMPLETED	Subthalamic Stimulation in Tourette’s Syndrome
NCT02679079	PHASE2	COMPLETED	Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome
NCT02879578	PHASE2	COMPLETED	Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome
NCT03066193	PHASE2	COMPLETED	Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome
NCT03247244	PHASE2	TERMINATED	Safety and Efficacy of Cannabis in Tourette Syndrome
NCT03325010	PHASE2	COMPLETED	Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
NCT03444038	PHASE2	COMPLETED	Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome